Answers are grounded in this paper and cite their sources.
Case report demonstrates rapid recovery from Bing–Neel syndrome in a woman following pirtobrutinib treatment.
Background Bing–Neel syndrome (BNS) is a rare neurological complication of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (WM), characterized by central nervous system (CNS) infiltration by malignant lymphoplasmacytic cells. Treatment guidelines are limited, and data on management after relapse on covalent Bruton tyrosine kinase inhibitors (BTKi) are scarce. Case presentation We report the case of a 76-year-old woman with WM who developed BNS and achieved prolonged neurological response with ibrutinib. After 50 months of therapy, she experienced CNS relapse. Treatment with the non-covalent BTKi pirtobrutinib led to rapid clinical improvement and maintained hematological response. Conclusion This case supports the potential efficacy of pirtobrutinib as salvage therapy for relapsed BNS after covalent BTKi exposure and adds to the limited real-world evidence in this rare clinical entity.
No takes yet. Share an insight, caveat, or question.
Vidali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: